Trials / Completed
CompletedNCT06920056
A Study of BGM0504 in Overweight or Obese Participants
A Single Center, Open-label, Fixed Sequence Trial, Investigating the Influence of BGM0504 Injection on Gastric Emptying and Pharmacokinetics of Metformin and Warfarin in Overweight or Obese Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the influence of BGM0504 injection on gastric emptying and Pharmacokinetics of metformin and warfarin in overweight or obese participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paracetamol | oral, postprandial |
| DRUG | Metformin Hydrochloride | Oral , Fasting |
| DRUG | Warfarin | Oral , Fasting |
| DRUG | BGM0504 | Administered SC |
Timeline
- Start date
- 2025-03-24
- Primary completion
- 2025-07-25
- Completion
- 2025-07-25
- First posted
- 2025-04-09
- Last updated
- 2025-09-09
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06920056. Inclusion in this directory is not an endorsement.